
==== Front
J Microbiol Biotechnol
J Microbiol Biotechnol
Journal of Microbiology and Biotechnology
1017-7825
1738-8872
The Korean Society for Microbiology and Biotechnology

39081248
10.4014/jmb.2404.04054
jmb-34-8-1592
Research article
Molecular and Cellular Microbiology (MCM)
Infection and Immunity
Characterization of a Small Plaque Variant Derived from Genotype V Japanese Encephalitis Virus Clinical Isolate K15P38
Kim Woo-Jin 12†
Lee Ah-Ra 12†
Hong Su-Yeon 12
Kim Sang-Hyun 12
Kim Jae-Deog 12
Kim Sung Jae 34
Oh Jae Sang 5
Shim Sang-Mu 6
Seo Sang-Uk 12*
1 Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Republic of Korea
2 Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
3 Vaxdigm Co., Ltd., Seoul 04798, Republic of Korea
4 Bio & Living Engineering Major, Global Leaders College, Yonsei University, Seoul 03722, Republic of Korea
5 Department of Neurosurgery, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
6 Division of Acute Viral Disease, Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Cheongju 28159, Republic of Korea
* Corresponding author Phone: +82-2-3147-8367 Fax: +82-2-2258-8969 E-mail: suseo@catholic.ac.kr.
† These authors contributed equally to this work.

28 8 2024
23 6 2024
23 6 2024
34 8 15921598
30 4 2024
31 5 2024
3 6 2024
Copyright © 2024 by the authors. Licensee KMB
2024
https://creativecommons.org/licenses/by/4.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license
Genotype V (GV) Japanese encephalitis virus (JEV) has been predominantly reported in the Republic of Korea (ROK) since 2010. GV JEV exhibits higher virulence and distinct antigenicity compared to other genotypes, which results in reduced efficacy of existing vaccines. Research on GV JEV is essential to minimize its clinical impact, but the only available clinical strain in the ROK is K15P38, isolated from the cerebrospinal fluid of a patient in 2015. We obtained this virus from National Culture Collection for Pathogens (NCCP) and isolated a variant forming small plaques during our research. We identified that this variant has one amino acid substitution each in the PrM and NS5 proteins compared to the reported K15P38. Additionally, we confirmed that this virus exhibits delayed propagation in vitro and an attenuated phenotype in mice. The isolation of this variant is a critical reference for researchers intending to study K15P38 obtained from NCCP, and the mutations in the small plaque-forming virus are expected to be useful for studying the pathology of GV JEV.

Japanese encephalitis virus
genotype V
mutant virus
attenuated variant
small plaque variant
==== Body
pmcIntroduction

The Japanese encephalitis virus (JEV), a member of the Flaviviridae family, is a positive-sense single-stranded RNA virus that is endemic to parts of temperate and tropical regions [1, 2]. Approximately 67,900 cases of Japanese encephalitis (JE) are reported annually in these endemic areas [2]. JE is a zoonotic disease transmitted by Culex mosquitoes, and various domestic and wild animals serve as amplifying hosts [3]. RNA viruses generally exhibit a higher mutation rate, allowing JEV to evolve into various variants and accumulate additional mutations during circulation within zoonotic hosts [4]. As a consequence, JEV has diverged and can be classified into five genotypes (GI to GV) based on the Envelope (E) gene sequence [5]. In earlier studies, GIII was the dominant strain of JEV, but since the mid-1990s, a clear prevalence of GI has been observed, and more recently, GIV and GV strains of JEV have been detected in some regions [6-9].

JE is preventable through vaccination and is effectively controlled in the Republic of Korea (ROK) through a nationwide vaccination program [10]. Since 2010, GV JEV has been continuously reported in the ROK, and the number of JE cases has concurrently increased [11]. Increased JE cases may be ascribed to inefficient vaccine efficacy, as some studies have shown that current commercially available JE vaccines are based on GIII and have weaker protective efficacy against GV compared to JEVs in other genotypes [12-14]. We have also reported that it is necessary to develop vaccines based on GV antigens to control infections by GV JEV more efficiently in animal models [15]. Although GV currently seems to be contained within the ROK, its previous detection in Malaysia and China suggests the possibility of a surge in other regions [16, 17]. Therefore, in addition to developing effective vaccines, it is essential to research the virological characteristics of GV strains to effectively respond their potential expansion.

To date, only two GV JEV isolates have been obtained from cerebrospinal fluid samples of JE patients: Muar, isolated in Singapore from Malaysian patients in 1952, and K15P38, isolated in the ROK in 2015 [8, 18]. Research on Muar has revealed that this virus exhibits higher virulence in mice compared to JEV strains belonging to other genotypes [17], suggesting a higher risk posed by GV strains to the human population. To analyze the characteristics of another GV JEV clinical isolate, K15P38, we obtained the isolate from the National Culture Collection for Pathogens (NCCP) under the code NCCP 43279 [19]. During the process of establishing a working bank for this virus, we were able to isolate a variant with smaller plaque size. From the point of patient infection to the creation of our working stock, there are numerous steps during which the variant could have emerged. However, it is difficult to pinpoint the exact moment of its origin. Nevertheless, considering the uniqueness and rarity of the GV clinical isolate, it is essential to characterize this small plaque variant.

Materials and Methods

Virus and Cells

The JEV isolate designated K15P38 utilized in this research was acquired from the NCCP with the assigned code of 43279. The Baby hamster kidney (BHK)-21 (C-13) cell line was procured from the Korean Cell Line Bank (KCLB). This cell line was cultured in Dulbeccós Modified Eagle Medium (DMEM) (HyClone, USA) supplemented with 10% fetal bovine serum (FBS) (HyClone) and 1× PS solution (Lonza, Switzerland). The culture conditions were maintained at 37°C in a 5% CO2 atmosphere. Viral stocks employed in the study were propagated at a multiplicity of infection (MOI) of 0.01 by infecting BHK-21 cells.

Plaque Assay

BHK-21 cells were seeded at a 3.0 × 105 cells per well in a 6-well plate and incubated at 37°C in a 5% CO2 atmosphere for 20 h prior to infection. The samples were serially diluted 10-fold in infection media composed of 2% FBS in DMEM, and were incubated with the cell monolayers for 1.5 h at 37°C in a 5% CO2 incubator. Following incubation, the monolayers were washed with DPBS (HyClone) and overlaid with 3 ml of media containing 2%SeaPlaque agarose (Lonza), 8% FBS, and 1× PS solution in Eagle’s Minimum Essential Medium (EMEM)(Welgene, Republic of Korea). After four days of incubation, the cells were fixed using 3 ml of 10% formalin (Biosesang, Republic of Korea) for two hours. The wells were then stained with a 1% crystal violet solution in 20%ethyl alcohol and thoroughly rinsed with tap water.

Isolation of Small Plaque Virus

The monolayer of BHK-21 cells in a 6-well plate was infected with 30 plaque-forming units (pfu) of NCCP 43279 to generate plaques as described previously. After four days of infection, cytopathic effects (CPE) were observed under a microscope, and plaques with small diameters were identified for isolation. Individual plaques were carefully picked using sterile pipette tips, following the removal of the overlay media via suction. These plaques were then used to inoculate fresh monolayers of BHK-21 cells. The isolated virus was propagated in BHK-21 cells through two additional passages, with successful isolation confirmed by the formation of homogeneous small plaques.

Sequencing of Viral Genome

Viral RNA was extracted from 200 μl of viral stock solution using the AccuPrep Viral RNA Extraction Kit (Bioneer, Republic of Korea). Complementary DNAs were synthesized and amplified employing the AccuPower RT-PCR Master Mix (Bioneer), following the manufacturer’s instructions with minor modifications. Sequencing of the amplified PCR products was performed in both directions (Cosmogenetech, Republic of Korea). The complete sequences were registered in GenBank under the accession numbers PP478074 for the large plaque isolate and PP582382 for the small plaque isolate.

In Vitro Virus Growth and Cytotoxicity

A monolayer of BHK-21 cells in a 6-well plate was infected with a 0.01 MOI of JEV in infection media for 1.5 h. Subsequently, the wells were washed with DPBS (HyClone) and maintained in 2 ml of infection media. At various time points, supernatants were collected for viral titer assessment. Additionally, the number of adherent cells remaining in each well was counted to evaluate cytotoxicity.

In Vivo Virus Characterization

Five-week-old female BALB/c mice were purchased from Orient Bio (Republic of Korea). Mice were intravenously infected with 106 pfu of JEV and then randomly divided into two groups. One group was sacrificed four days post-infection and transcardially perfused with 20 ml of cold PBS prior to harvesting the brain tissue. The second group was monitored to assess lethality for 15 days post-infection. The humane endpoint was set at a body weight reduction of 20% or more compared to the initial weight. All mice were anesthetized with isoflurane and euthanized by CO2 inhalation. All animal research was conducted under protocols approved by the Institutional Animal Care and Use Committee at The Catholic University of Korea (approval no. CUMS-2023-0264-01).

Histology

Mouse brains were carefully extracted and fixed in 10% formalin. Tissues were sliced into 5 μm sections and then stained with hematoxylin and eosin (H&E). All specimens were digitized using the Pannoramic MIDI Scanner (3DHistech, Hungary). A histological damage scoring system, adapted from a previous study, ranging from 0 (no damage) to 4 (extreme damage) was used to quantify the severity of the changes in the brain tissue.

Flow Cytometry

The brain tissue was finely minced using a clean blade and incubated with a digestion buffer consisting of 1 mg/ml collagenase type 4 (Worthington Biochemical Corp., USA) and 50 μg/ml DNase I (Roche) in (HyClone) for 1 h at 37°C on a shaker. The samples were then sieved through a 70-μm nylon mesh strainer and centrifuged to collect the pellet. For density gradient centrifugation, the pellet was resuspended in 30% Percoll in PBS and layered into a centrifuge tube containing 37% Percoll overlaid on 70% Percoll. Following centrifugation, mononuclear cells were isolated from the interphase. A total of 1 × 105 mononuclear cells were stained for 20 min at 4°C in FACS buffer comprising 2% FBS and 1 mM EDTA in PBS, using combinations of the following antibodies: CD45 (30-F11), CD11b (M1/70), and Ly6G (1A8) from BioLegend (USA); Ly6C (AL-21) from BD Biosciences (USA). The cells were then washed and resuspended in cold FACS buffer. Data were analyzed using the BD FACSCanto system and FlowJo v10.8.1 software (BD Biosciences).

Cytokine Measurement

The brain was homogenized using the FastPrep-24 5G bead beating system (MP Biomedicals, USA) along with the homogenization kit (IGT-25ZS, InnoGeneTech, Republic of Korea) in 1 ml of PBS. The supernatants were collected and quantified using the Cytometric Bead Array Mouse Inflammation Kit (BD Biosciences) with a BD FACSCanto flow cytometer. Data were analyzed with the FCAP Array Software v3.0 (BD Biosciences).

Statistical Analysis

Values represent the mean and standard deviation (SD) for all experiments. All data were analyzed using GraphPad Prism v9.5 (GraphPad, USA). Statistical analyses were performed using Student's t-test (two-tailed), analysis of variance (ANOVA), and the Kaplan-Meier method. Statistical significance was determined at a P-value of less than 0.05, denoted as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Results

Isolation of Small Size Plaque-Forming Virus

While establishing the NCCP 43279 master bank, we observed plaques of smaller size during the quantification of viral titers (Fig. 1A). We repeated a plaque assay across multiple wells and found that the proportion of small-sized plaques was 21.05 ± 3.19% among all plaques (Fig. 1B). We isolated viruses from plaques of different sizes, and for this study, we have designated each isolate based on plaque size as either 'Largé or 'Small'.

Sequencing of Isolated K15P38 Viruses

We sequenced the nucleotide sequence of the entire open reading frame (ORF) of the Large and Small viruses. Differences in the sequences were identified at positions 622, 2379, 4860, and 10250 of the complete ORF, corresponding to the genes coding for PrM, E, NS3, and NS5, respectively (Fig. 2A). Among these, the T-to-C mutation at position 622 and the C-to-T mutation at position 10250 resulted in C208R and T3418I substitutions in the polyprotein, respectively (Fig. 2B).

In Vitro Characterization of K15P38 Variants

Plaque assays using isolated Large and Small isolates revealed generally homogenous plaques of different sizes (Fig. 3A). The plaque sizes were 2.14 ± 0.43 mm for Large and 1.08 ± 0.28 mm for Small (Fig. 3B). When proliferated in vitro, Small isolates showed slower propagation with a lower peak titer (5.5 ± 3.5 × 106 pfu/ml) compared to Large isolates (3.3 ± 1.5 × 107 pfu/ml) at 2 days post-infection (Fig. 3C). However, cytotoxicity did not show significant differences between the two isolates throughout the culture period (Fig. 3D).

In Vivo Characterization of K15P38 Variants

To investigate the virulence of isolates in vivo, five-week-old female BALB/c mice were infected intravenously with 106 pfu of either Large or Small virus. While all mice infected with Large virus succumbed to death by 6 days post-infection, 27.3% of mice infected with Small virus survived (Fig. 4A). Differences in body weight between the two groups appeared from day 4, and survivors infected with the Small virus began to regain weight from day 7 (Fig. 4B). When a lower dose (105 pfu) of either Large or Small virus was used, all mice infected with the Small virus survived, while only 40% of mice infected with the Large virus survived (Fig. 4C). The body weight of Large virus-infected mice dropped to its lowest at day 6, while no significant weight loss was observed in Small virus-infected mice (Fig. 4D). In accordance with weight loss and survival rates, mice infected with the Large virus exhibited a higher viral burden in the brain on day 4 (Fig. 4E). Furthermore, more severe tissue pathology was observed in cases of Large virus infection (2.67 ± 0.82) compared to those with the Small virus (1.33 ± 1.51), although the difference did not reach statistical significance (Fig. 4F).

Next, we examined the immunopathology in mice infected with K15P38 variants. Although there were individual variations, expression of neuropathic cytokines such as TNF-α, MCP-1, and IL-6 was observed in the brains infected with the Large virus, whereas almost no cytokine detection occurred in cases of Small virus infection (Fig. 5A). In the peripheral blood, TNF-α and MCP-1 were detected in mice infected with the Small virus, although their expression levels were relatively lower than in mice infected with the Large virus (Fig. 5B). Myeloid cell infiltration in the brain exhibited a pattern similar to that of the cytokines. Mice infected with the Large virus showed significantly higher myeloid cell (CD45highCD11b+) infiltration compared to those infected with the Small virus, with these myeloid cells predominantly comprising monocytes and neutrophils (Fig. 5C). Small virus infection did not show a statistically significant increase in immune cell infiltration compared to mock-infected mice. Overall, the differences between the Large and Small isolates were more pronounced in vivo than in vitro, demonstrating an overall attenuated phenotype.

Discussion

Viruses with RNA genomes, including JEV, inherently possess higher mutation rates compared to those with DNA genomes [20]. Examining the mutant characteristics of circulating viruses is crucial for understanding the diseases they cause, as these mutations enable the virus to interact continuously with the host. The importance of studying the GV genotype of JEV in ROK stems from its unprecedented dominance in detections, which coincides with the timing of increases in patient cases [11, 21-23]. However, despite its significance, K15P38 is the only clinical isolate of GV JEV available for research in the ROK. Therefore, securing and studying variants of this virus is critical for understanding the epidemiology of JE locally and potentially reducing the impact of this virus in other endemic areas.

The large plaque-forming virus isolated from NCCP 43279 had an amino acid sequence that was 100% identical to that previously reported for K15P38. However, the small plaque-forming virus exhibited two amino acid substitutions, found in the PrM and NS5 proteins, respectively. While the E protein primarily plays a crucial role related to antigenicity [24-26], recent studies have demonstrated that specific amino acid substitutions in the non-structural (NS) proteins of JEV significantly influence the growth, virulence, neurovirulence, and replication of the GIII strains [27-29]. Moreover, mutations in the PrM domain have been found to be involved in the attenuation of virulence in the GIII strains [30, 31]. However, mutation studies on the GV genotype have not been extensively conducted due to the scarcity of isolated strains, highlighting the need for further research on virus mutations in GV strains as well.

The PrM protein of JEV plays a pivotal role in both the formation of the virus capsid and the regulation of new virus replicates being secreted from cells [32, 33]. If the PrM protein is modified or defective, the virus capsid formation does not occur properly, leading to a decrease in the virulence of the virus [33]. Recent research has indicated that not only JEV but also the PrM of the Zika virus is involved in pathogenicity in mice [34, 35]. Additionally, the NS5 protein also plays a central role in the replication of viral RNA, and mutations at specific sites of this protein can greatly influence the virus’s replicative ability and pathogenicity [36, 37]. In this study, we reported that amino acid substitutions in the K15P38 variant occurred in two important functional regions. However, further research using reverse genetic technique will be necessary to demonstrate how the mutations we identified in the PrM and NS5 proteins induce small plaque formation and attenuated virulence in mice [38] .

Similarly, the small virus did not exhibit noticeable immunopathology in the brains of infected mice four days post-infection. While we expected mice infected with the small virus to exhibit attenuated pathology due to a lower viral burden compared to those infected with the Large virus, the cytokine levels and myeloid cell infiltration observed were even lower than anticipated. We believe this difference is characteristic of the time point at which the analysis was conducted. We set the time point to check immunopathology on day 4 post-infection because mice infected with 105 pfu of the large virus succumbed to death by this time. However, at this point, mice infected with the small virus had not yet shown significant weight changes. This suggests that the spread of the small virus starts later, and therefore, the pathology observed at this time point reflects a delayed onset characteristic.

Overall, we are reporting on variants derived from K15P38, particularly noting that substitutions in PrM and NS5 significantly influence the in vitro and in vivo characteristics of these variants. While further in-depth studies on more GV JEV isolates are necessary, the findings from this study are expected to be useful for future molecular biological studies of pathogenesis and the development of attenuating vaccine strains.

Acknowledgments

This work was supported by the National Research Foundation of Korea (NRF) funded by the Korea government (MSIT) (grant numbers: 2022R1F1A1074547) and the Korea National Institute of Health (KNIH)(project number: 2024ER170100).

Fig. 1 Identification of small plaque-forming K15P38 variant.

(A) Representative plaque morphology of the NCCP 43279 strain. Small plaques were observed and are indicated by blue arrows. (B) The proportion of large and small plaques was measured from 10 individual wells, with approximately 50 plaques observed per well. Data are shown as mean ± SD values. ****p < 0.0001.

Fig. 2 Gene mutations and amino acid substitutions of the small plaque-forming variant.

(A) Location of four mutations on the viral genome. Mutations are indicated with black arrowheads at specific position numbers. Position numbers are counted based only on the open reading frame (ORF), excluding the untranslated regions. (B) Positions of amino acids on the translated polyprotein corresponding to the genetic mutations. Locations where substitutions occurred are highlighted in bold, with the substituted amino acids shown. nt: nucleotide, aa: amino acid.

Fig. 3 In vitro characterization of K15P38 variants.

(A) Representative plaque images for Large and Small viruses. BHK-21 cells were infected with either virus, and images were captured 80 hours post-infection. (B) The diameter of thirty individual plaques from each virus type was measured in millimeters. (C, D) BHK-21 cells were infected with either the Large or Small virus at an MOI of 0.01. Viral titer (C) and the number of adherent cells (D) were assessed to examine the growth kinetics and cytotoxicity, respectively. Data represent mean ± SD values pooled from two independent experiments in duplicate wells (n = 4). *p < 0.05, ****p < 0.0001.

Fig. 4 In vivo characterization of K15P38 variants.

(A-D) BALB/c mice were intravenously infected with 105 (A, B) or 106 (C, D) pfu of either Large or Small virus (n = 10-15). Survival rate (A, C) and body weight (B, D) of the infected mice were monitored for 15 days post-infection. (E, F) Viral titers (E) and histopathological scores (F) were measured in the brains of mice infected with 106 pfu of either Large or Small virus at 4 days post-infection. Data represent mean ± SD values pooled from two independent experiments (n = 6). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Fig. 5 Immunopathogenicity of K15P37 variants.

BALB/c were intravenously infected with 106 pfu of either Large or Small virus and sacrificed at 4 days post-infection (n = 6). (A, B) The levels of TNF-α, MCP-1, and IL-6 were determined in brain (A) and plasma (B) samples. (C) Representative flow cytometry plot and analysis of myeloid cell infiltration, including monocytes and neutrophils, in the brain. Data represent mean ± SD. *p < 0.05, **p < 0.01, ****p < 0.0001.

Conflict of Interest

The authors have no financial conflicts of interest to declare.
==== Refs
References

1 Solomon T 2006 Control of Japanese encephalitis--within our grasp? N. Engl. J. Med. 355 869 871 10.1056/NEJMp058263 16943399
2 Campbell GL SL Hills M Fischer JA Jacobson CH Hoke JM Hombach 2011 Estimated global incidence of Japanese encephalitis: a systematic review Bull World Health Organ. 89 766 774 774a 774e 10.2471/BLT.10.085233 22084515
3 van den Hurk AF SA Ritchie JS Mackenzie 2009 Ecology and geographical expansion of Japanese encephalitis virus Annu. Rev. Entomol. 54 17 35 10.1146/annurev.ento.54.110807.090510 19067628
4 Villa TG AG Abril S Sanchez T de Miguel A Sanchez-Perez 2021 Animal and human RNA viruses: genetic variability and ability to overcome vaccines Arch. Microbiol. 203 443 464 10.1007/s00203-020-02040-5 32989475
5 Solomon T H Ni DW Beasley M Ekkelenkamp MJ Cardosa AD Barrett 2003 Origin and evolution of Japanese encephalitis virus in southeast Asia J. Virol. 77 3091 3098 10.1128/JVI.77.5.3091-3098.2003 12584335
6 Li MH SH Fu WX Chen HY Wang YH Guo QY Liu 2011 Genotype v Japanese encephalitis virus is emerging PLoS Negl. Trop. Dis. 5 e1231 10.1371/journal.pntd.0001231 21750744
7 Kim H GW Cha YE Jeong WG Lee KS Chang JY Roh 2015 Detection of Japanese encephalitis virus genotype V in Culex orientalis and Culex pipiens (Diptera: Culicidae) in Korea PLoS One 10 e0116547 10.1371/journal.pone.0116547 25658839
8 Woo JH YE Jeong JE Jo SM Shim J Ryou KC Kim 2020 Genetic characterization of Japanese encephalitis virus genotype 5 isolated from patient, South Korea, 2015 Emerg. Infect. Dis. 26 1002 1006 10.3201/eid2605.190977 32310056
9 Sikazwe C MJ Neave A Michie P Mileto J Wang N Cooper 2022 Molecular detection and characterisation of the first Japanese encephalitis virus belonging to genotype IV acquired in Australia PLoS Negl. Trop. Dis. 16 e0010754 10.1371/journal.pntd.0010754 36409739
10 Kwak BO YJ Hong DH Kim 2022 Changes in age-specific seroprevalence of Japanese encephalitis virus and impact of Japanese encephalitis vaccine in Korea Clin. Exp. Pediatr. 65 108 114 10.3345/cep.2020.01984 34592804
11 Lee AR JM Song SU Seo 2022 Emerging Japanese encephalitis virus genotype V in Republic of Korea J. Microbiol. Biotechnol. 32 955 959 10.4014/jmb.2207.07002 35879275
12 Monath TP 2002 Japanese encephalitis vaccines: current vaccines and future prospects Curr. Top. Microbiol. Immunol. 267 105 138 10.1007/978-3-642-59403-8_6 12082985
13 Halstead SB J Jacobson K Dubischar-Kastner 2012 Japanese encephalitis vaccines. Vaccines, 6th ed.; Plotkin, SA, Orenstein, WA, Offit, PA, Eds. 312 351
14 Cao L S Fu X Gao M Li S Cui X Li 2016 Low protective efficacy of the current Japanese encephalitis vaccine against the emerging genotype 5 Japanese Encephalitis Virus PLoS Negl. Trop. Dis. 10 e0004686 10.1371/journal.pntd.0004686 27139722
15 Kim JD AR Lee DH Moon YU Chung SY Hong HJ Cho 2024 Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus Emerg. Microbes Infect. 13 2343910 10.1080/22221751.2024.2343910 38618740
16 de Wispelaere M MP Frenkiel P Despres 2015 A Japanese encephalitis virus genotype 5 molecular clone is highly neuropathogenic in a mouse model: impact of the structural protein region on virulence J. Virol. 89 5862 5875 10.1128/JVI.00358-15 25787283
17 Tajima S K Yagasaki A Kotaki T Tomikawa E Nakayama ML Moi 2015 In vitro growth, pathogenicity and serological characteristics of the Japanese encephalitis virus genotype V Muar strain J. Gen. Virol. 96 2661 2669 10.1099/vir.0.000213 26048886
18 Hale JH KA Lim PH Chee 1952 Japanese type B encephalitis in Malaya Ann. Trop. Med. Parasitol. 46 220 226 10.1080/00034983.1952.11685526 13008352
19 Lee AR SH Kim SY Hong SH Lee JS Oh KY Lee 2024 Characterization of genotype V Japanese encephalitis virus isolates from Republic of Korea Emerg. Microbes Infect. 13 2362392 10.1080/22221751.2024.2362392 38808613
20 Holland J K Spindler F Horodyski E Grabau S Nichol S VandePol 1982 Rapid evolution of RNA genomes Science 215 1577 1585 10.1126/science.7041255 7041255
21 Lee DW YJ Choe JH Kim KM Song H Cho GR Bae 2012 Epidemiology of Japanese encephalitis in South Korea, 2007-2010 Int. J. Infect. Dis. 16 e448 e452 10.1016/j.ijid.2012.02.006 22497964
22 Sunwoo JS KH Jung ST Lee SK Lee K Chu 2016 Reemergence of Japanese encephalitis in South Korea, 2010-2015 Emerg. Infect. Dis. 22 1841 1843 10.3201/eid2210.160288 27648677
23 Bae W JH Kim J Kim J Lee ES Hwang 2018 Changes of epidemiological characteristics of Japanese encephalitis viral infection and birds as a potential viral transmitter in Korea J. Korean Med. Sci. 33 e70 10.3346/jkms.2018.33.e70 29441740
24 Kimura-Kuroda J K Yasui 1986 Antigenic comparison of envelope protein E between Japanese encephalitis virus and some other flaviviruses using monoclonal antibodies J. Gen. Virol. 67 2663 2672 10.1099/0022-1317-67-12-2663 2432163
25 Srivastava AK Y Aira C Mori Y Kobayashi A Igarashi 1987 Antigenicity of Japanese encephalitis virus envelope glycoprotein V3 (E) and its cyanogen bromide cleaved fragments examined by monoclonal antibodies and Western blotting Arch. Virol. 96 97 107 10.1007/BF01310993 2441683
26 Hawkes RA JT Roehrig AR Hunt GA Moore 1988 Antigenic structure of the Murray valley encephalitis virus E glycoprotein J. Gen. Virol. 69 1105 1109 10.1099/0022-1317-69-5-1105 2453607
27 Tajima S S Taniguchi E Nakayama T Maeki T Inagaki CK Lim 2020 Amino acid at position 166 of NS2A in Japanese Encephalitis Virus (JEV) is associated with in vitro growth characteristics of JEV Viruses 12 709 10.3390/v12070709 32629892
28 Zhou Y R Wu Q Zhao YF Chang X Wen Y Feng 2018 Mutation of I176R in the E coding region weakens Japanese encephalitis virus neurovirulence, but not its growth rate in BHK-21 cells Arch. Virol. 163 1351 1355 10.1007/s00705-018-3765-2 29411136
29 Tan N C Chen Y Ren R Huang Z Zhu K Xu 2023 Nucleotide at position 66 of NS2A in Japanese encephalitis virus is associated with the virulence and proliferation of virus Virus Genes 60 9 17 10.1007/s11262-023-02036-5 37938470
30 Yang J H Yang Z Li W Wang H Lin L Liu 2017 Envelope protein mutations L107F and E138K are important for neurovirulence attenuation for Japanese encephalitis virus SA14-14-2 strain Viruses 9 20 10.3390/v9010020 28117725
31 Gromowski GD CY Firestone SS Whitehead 2015 Genetic determinants of Japanese encephalitis virus vaccine strain SA14-14-2 that govern attenuation of virulence in mice J. Virol. 89 6328 6337 10.1128/JVI.00219-15 25855730
32 Poonsiri T GSA Wright T Solomon SV Antonyuk 2019 Crystal structure of the Japanese encephalitis virus capsid protein Viruses 11 623 10.3390/v11070623 31284608
33 Kim JM SI Yun BH Song YS Hahn CH Lee HW Oh 2008 A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice J. Virol. 82 7846 7862 10.1128/JVI.00789-08 18524814
34 Yuan L XY Huang ZY Liu F Zhang XL Zhu JY Yu 2017 A single mutation in the prM protein of Zika virus contributes to fetal microcephaly Science 358 933 936 10.1126/science.aam7120 28971967
35 Kato F S Tajima E Nakayama Y Kawai S Taniguchi K Shibasaki 2017 Characterization of large and small-plaque variants in the Zika virus clinical isolate ZIKV/Hu/S36/Chiba/2016 Sci. Rep. 7 16160 10.1038/s41598-017-16475-2 29170504
36 Edward Z T Takegami 1993 Localization and functions of Japanese encephalitis virus nonstructural proteins NS3 and NS5 for viral RNA synthesis in the infected cells Microbiol. Immunol. 37 239 243 10.1111/j.1348-0421.1993.tb03206.x 8321152
37 Li C D Di H Huang X Wang Q Xia X Ma 2020 NS5-V372A and NS5-H386Y variations are responsible for differences in interferon alpha/beta induction and co-contribute to the replication advantage of Japanese encephalitis virus genotype I over genotype III in ducklings PLoS Pathog. 16 e1008773 10.1371/journal.ppat.1008773 32881988
38 Ishikawa T M Abe M Masuda 2015 Construction of an infectious molecular clone of Japanese encephalitis virus genotype V and its derivative subgenomic replicon capable of expressing a foreign gene Virus Res. 195 153 161 10.1016/j.virusres.2014.10.010 25451067
